The global bioprocess technology market size was evaluated at USD 20.8 billion in 2022 and is projected to hit around USD 79 billion by 2032, growing at a CAGR of 14.26% during the forecast period 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Bioprocess technology describes the industries that utilize living cells or their individual parts to convert desired substrates. The key advantages of the ado-trial application of biological Bioprocesses over traditional chemical ones include the production of renewable by-products, the need for mild reaction conditions, and their increased focus and efficiency (biomass).
The development of Recombinant DNA technology has boosted and broadened the possibilities of Bioprocesses. Bioprocess technology, which deals with methods that mix the entire live organism or its component parts with nutrients to make specialized chemicals, reagents, and biotherapeutics, is a crucial part of biotechnology. The techniques serve as the cornerstone for translating advances in the life sciences into useful industrial goods.
Among the many processes related to Bioprocess technology are substrates and media, biocatalysts, volume production, downstream processing, purification, and final processing. Over the past few years, the Bioprocess technology industry has seen a rise in the development of numerous next-generation biopharmaceutical products.
The market of Bioprocess technology is being driven by an increasing emphasis on preventative measures as well as alternative medications for certain needs. Key elements affecting overall market growth include the opening of new production facilities and the expansion of existing ones in emerging regions. The development of new technologies to address performance and quality challenges related to the production of Bioprocess products has resulted in increased investments over the past five years, which has led to a significant advancement in the field of Bioprocess technology.
Additionally, the pharmaceutical industry is projected to have a sizable demand for Bioprocess technology due to the rise in infectious and chronic diseases such as cancer. Outsourcing biopharmaceuticals is becoming a successful method of addressing patients' unmet medical requirements. It has caused a growth in Bioprocessing systems with greater throughput and process efficiency.
The procedures of legal compliance benefit due to Bioprocess technology. Since single-use systems offer cost-efficiency and technological breakthroughs due to expanding capacities and capabilities, many bio-pharmaceutical businesses are choosing to adopt them. However, the market expansion for Bioprocess technologies is constrained by tight supervision regulations and costly technology costs.
| Report Coverage | Details |
| Market Size in 2022 | USD 20.8 Billion |
| Market Size by 2032 | USD 79 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 14.26% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Largest Market | North America |
| Segments Covered | By Product Type, By Application, By End-Use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
Key Market Drivers
With the rise in chronic diseases, biopharmaceutical companies are increasing their R&D efforts - The desire for advancements in Bioprocess technology is being fueled by the rising frequency of cancer and other chronic disorders. Market participants in the worldwide Bioprocess technology market is seeing increased revenue prospects because of the pharmaceutical industry's ongoing expansion. Pharmaceutical and biotechnology businesses have increased the manufacturing of treatments and supported research studies and other investigations as a result of the growth in demand for proteins and vaccines.
Outsourcing of biopharmaceuticals is becoming more popular as a technique to meet patients' unmet medical requirements. This has increased the use of Bioprocessing systems with higher throughput and process efficiency. These solutions provide a benefit for following legal compliance procedures. Single-use systems are becoming more popular among biopharmaceutical businesses since they offer cost-efficiency and technological breakthroughs owing to expanding capacities and capabilities.
Continuous R&D activities are improving bioprocess technology - The market for Bioprocess technology is expanding because of ongoing technological advancements. The assembly of biomaterials such as catalysts, anti-microbial drugs, food and farming products, antibodies, and drug supplements finds value in Bioprocess technology. Additionally, this technology identifies applications to produce biodegradable and environmentally friendly chemicals, the development of alternative treatments for diseases, and facilitation of the production and evaluation of more secure food products.
Bioprocesses may find applications in various fields where substance processes are currently used as methods and instruments become more advanced. The creation of media, the development of biocatalysts, and the design of substrates for bioreactors are examples of Bioprocessing activities that combine biological, engineering, and mathematical processes. Companies in the Bioprocess technology market are diversifying towards the use of hybrid systems in their facilities as they become more aware of the advantages of single-use Bioprocessing technologies.
Key Market Challenges
Strict regulations - The market players in the Bioprocess technology sector find it difficult to advance at the growth pace. Many governments around the world have already taken action, and some of them are choosing to impose severe regulation policies backed by the high cost of the market instruments that are preventing the market from expanding during the projected period.
COVID-19 challenges - The unexpected onset of the COVID-19 pandemic in late 2019 and early 2020 has been one of the primary problems encountered by the leading industry players in the Bioprocess technology market size. Concerns and tensions to protect the world's population from the sickness arose because of the sudden and rapid spread of the coronavirus disease. Global governments were forced to enforce tight rules in the form of standards such as social distancing and the implementation of temporary and permanent lockdowns because there was no vaccine or appropriate medicine.
The government is playing a significant part in assisting the Bioprocess technology market to recover from everything that has been disrupted because of the pandemic's entrance and acceleration of various trends in 2020. The market players anticipated a rebound in demand patterns as the lockdown restrictions are lifted, which will let them concentrate on new innovations before launching those products internationally to satisfy the active wants of the worldwide target audience during the forecast period.
Key Market Opportunities
Technological advancement - Increased financing and investment from the government, the public sector, and major market participants aid in the growth of the market's size during the current forecast period. By using the right investment policies to assist the Bioprocess technology market to grow and serve the needs of a wider audience, biotechnology and pharmaceutical firms are improving their operations.
Based on the product category, the biologics safety testing market is anticipated to expand quickly over the next few years. Manufacturers assess the safety of biologics for impurities such as viruses, bacteria, and mycoplasma. The validation and process control of finished goods, as well as the quality control of raw materials, depend on this procedure the most. The market expansion is attributed to factors including rising pharmaceutical outsourcing and increasing government backing for the biotechnology and pharmaceutical industries.
Recombinant proteins are expected to have a rapid increase over the forecast period based on application. The market is expanding because of an increase in demand for recombinant proteins in medicinal applications. The most effective treatments for a variety of illnesses, including cancer, diabetes, infectious infections, anemia, and hemophilia, are provided by recombinant therapeutic proteins. Antibodies, interleukin, hormones, anticoagulants, enzymes, and FC fusion proteins are examples of frequently used therapeutic proteins. As a result, the segment is expanding as the incidence of chronic diseases like cancer and diabetes rises.
The category of biopharmaceutical firms is expected to hold the greatest market share during the projection period by end-use. The production of a variety of next-generation or highly innovative biopharmaceutical products using Bioprocess technology has grown in popularity in the market for Bioprocess technology over the past few years.
Due to continual technological advancements in Bioprocessing techniques, the range of their applications has further enlarged. Further fostering the segment's growth is the constantly expanding interest in fields of life science such as biotechnology, pharmacology, and toxicology as well as the rising need for improved Bioprocess technology for the creation of innovative pharmaceuticals and vaccines.
North America is anticipated to lead the market during the forecast period an accounted more than 40% of revenue share in 2022. The existence of large companies, the high frequency of chronic diseases treated mostly with biopharmaceuticals in the area, and the developed healthcare infrastructure all contribute to the market's growth. In addition, favorable government efforts and a rise in research partnership numbers are among the factors anticipated to fuel market expansion. Due to its pro-healthcare legislation, large patient population, and developed healthcare market, the U.S. has the largest share in this region.
The market is expanding because of rising biotechnology and pharmaceutical companies' spending on research and development. India Brand Equity Foundation estimates that India’s biotech sector accounts for 2% of the global market. About 800 companies make up India's biotechnology sector, which was projected to be worth $11.6 billion by the end of 2021. In order to grow this sector into an industry that will be USD 100 billion by 2025, the government invested USD 5 billion to create human resources, infrastructure, and research efforts.
Furthermore, biopharma is one of the largest sectors across the globe. Several international businesses have aggressively partnered with Indian businesses because of India's promising generic biotechnology future. The Telangana government biotech and pharma Flagship event named BioAsia 2017 was able to attract investment of about 507.3 million USD. For biotechnology, sector agreements were signed by 37 companies at the Global Summit of Gujarat which took place in the same year. The high cost of the instruments and the rigorous regulatory laws, however, are the downsides of the market expansion.
Segments Covered in the Report
(Note*: We offer reports based on sub-segments as well. Kindly, let us know if you are interested)
By Product Type
By Application
By End-Use
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
